DexCom (NASDAQ:DXCM – Get Free Report) was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating in a research report issued on Monday. Several other brokerages also recently issued reports on DXCM. Barclays upped their target price on shares of DexCom from $115.00 to $138.00 and gave the stock an “equal […]
Raymond James Trust N.A. cut its stake in shares of DexCom, Inc. (NASDAQ:DXCM – Free Report) by 6.4% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 4,640 shares of the medical device company’s stock after selling 318 shares during the period. […]
Canaccord Genuity Group Raises DexCom (NASDAQ:DXCM) Price Target to $150 00 themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Emerald Advisers LLC trimmed its holdings in shares of DexCom, Inc. (NASDAQ:DXCM – Free Report) by 52.6% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,212 shares of the medical device company’s stock after selling 2,452 shares during the period. […]
DexCom (NASDAQ:DXCM – Get Free Report) and Regenicin (OTCMKTS:RGIN – Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, analyst recommendations, earnings and risk. Valuation and Earnings This table compares DexCom and Regenicin’s top-line […]